Cardiac Biomarkers Market Report by Type (Troponins (T and I), Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Others), Location of Testing (Laboratory Testing, Point of Care Testing), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Region 2025-2033

Cardiac Biomarkers Market Report by Type (Troponins (T and I), Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Others), Location of Testing (Laboratory Testing, Point of Care Testing), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A1178

Market Overview:

The global cardiac biomarkers market size reached USD 11.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.2 Billion by 2033, exhibiting a growth rate (CAGR) of 7.22% during 2025-2033.

Report Attribute
 Key Statistics 
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 11.5 Billion
Market Forecast in 2033
USD 22.2 Billion
Market Growth Rate 2025-2033 7.22%


Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.

Global Cardiac Biomarkers Market Drivers:

Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac biomarkers market report, along with forecasts at the global and regional level from 2025-2033. Our report has categorized the market based on type, location of testing, and application.

Breakup by Type:

  • Troponins (T and I) 
  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP 
  • Ischemia Modified Albumin (IMA) 
  • Others
     

Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.

Breakup by Location of Testing:

  • Laboratory Testing 
  • Point of Care Testing
     

Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.

Breakup by Application:

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
     

Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.

Regional Insights:

Cardiac Biomarkers Market Report

  • North America
  • Asia Pacific
  • Europe
  • Middle East and Africa
  • Latin America
     

Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Type, Location of Testing, Application, Region
Region Covered North America, Asia Pacific, Europe, Latin America, Middle East and Africa
Companies Covered Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global cardiac biomarkers market was valued at USD 11.5 Billion in 2024.

We expect the global cardiac biomarkers market to exhibit a CAGR of 7.22% during 2025-2033.

The rising number of patients suffering from ACS due to shifting dietary patterns, coupled with the increasing consumer awareness towards early diagnosis and treatment of cardiovascular diseases, is currently driving the global cardiac biomarkers market.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of several elective surgeries pertaining to cardiac diseases to mitigate the risk of coronavirus infection upon hospital visits.

Based on the location of testing, the global cardiac biomarkers market has been classified into laboratory testing and point of care testing. Currently, laboratory testing holds largest market share.

Based on the application, the global cardiac biomarkers market can be bifurcated into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Among these, myocardial infarction accounts for the majority of the total market share.

On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.

Some of the major players in the global cardiac biomarkers market include Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson and Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare, and Thermo Fisher Scientific.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Cardiac Biomarkers Market Report by Type (Troponins (T and I), Myocardial Muscle Creatine Kinase (CK-MB), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Others), Location of Testing (Laboratory Testing, Point of Care Testing), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials